Head-to-head evidence
mirikizumab vs risankizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
mirikizumab · Omvoh
Marketed by Eli Lilly
NCT03524092 · Phase 3 · completed
Randomized (re-randomization of induction responders), double-blind, placebo-controlled, adequately powered (n=544 in the key comparison), hard composite clinical/endoscopic primary endpoint that was statistically significant in the favorable direction (p<0.001) — meeting the 'strong' definition's full test.
Next expected readout: May 2027 · NCT07186101 (registry estimate)
risankizumab · Skyrizi
Marketed by AbbVie
NCT03398148 · Phase 2/3 · completed
Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.
Next expected readout: August 2027 · NCT06880744 (registry estimate)
Crohn's Disease
Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline
mirikizumab · Omvoh
Marketed by Eli Lilly
NCT03926130 · Phase 3 · completed
Randomized, triple-masked, placebo-controlled, adequately powered (n=1158 overall, ~778 in the placebo/mirikizumab primary comparison), with hard endoscopic (SES-CD response) and clinical remission co-primary endpoints, both meeting statistical significance (p<0.000001) favoring mirikizumab over placebo.
Next expected readout: June 2027 · NCT07483099 (registry estimate)
risankizumab · Skyrizi
Marketed by AbbVie
NCT03104413 · Phase 3 · completed
Design meets the 'strong' test: randomized, double-blind, placebo-controlled, adequately powered (n~600), with a hard endoscopic co-primary endpoint (SES-CD response) plus CDAI clinical remission, and both primary endpoint comparisons were statistically significant in the favorable direction for both doses vs placebo.
Next expected readout: March 2027 · NCT06063967 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mirikizumab's landscape · risankizumab's landscape